secwatch.observer — SEC 8-K summary
======================================

Issuer:     STANDARD BIOTOOLS INC. (LAB)
CIK:        0001162194
Form:       8-K
Filed at:   2026-01-08T23:59:59+00:00
Accession:  0001193125-26-006996
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Standard BioTools prelim Q4 revenue ~$56M, FY2025 ~$185M; SomaLogic sale on track
--------------------------------------------------------------------------------

- Q4 combined rev ~$56M (continuing ops ~$24M); FY2025 combined ~$185M (continuing ~$85M).
- Exceeded guidance and expectations for both combined and continuing operations.
- SomaLogic sale to Illumina on track to close H1 2026; expects ~$550M cash post-close.
- Base business on track to positive adjusted EBITDA; positioned for disciplined M&A.
- Streamlined operations and improved cost structure exiting year as leaner organization.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1162194/000119312526006996/0001193125-26-006996-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1162194/000119312526006996/lab-20260108.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-006996

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer